Plasmid vector and construction method thereof as well as exogenous gene expression system and method for responding to IFN-gamma induction in iPSC (induced pluripotent stem cell) constructed by using plasmid vector
By constructing an exogenous gene expression system in response to IFN-γ induction in iPSC, using CRISPR/Cas9 technology and endogenous B2M gene regulatory elements, the problem of uneven exogenous gene expression in iPSC is solved, and efficient exogenous gene expression is achieved and stability.
Patent Information
- Application Number
- CN202411108270.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-13
AI Technical Summary
In iPSC, conventional mammalian genetic engineering expression systems are susceptible to epigenetic modifications due to the exogenous promoter and transcription termination sequence, resulting in uneven expression and reduced function of exogenous genes, making it difficult to work effectively.
Design a plasmid vector containing gene cleavage vector and template repair vector. A foreign gene expression system that responds to IFN-γ induction is constructed in iPSC through CRISPR/Cas9 technology, and the expression regulatory elements of endogenous B2M genes are used to avoid exogenous initiation. The intervention of the sub- and transcription termination sequences enables efficient expression of multiple exogenous genes.
High-level expression of exogenous genes during IFN-γ treatment is achieved, the intervention and expression inequality of exogenous gene expression regulatory elements is avoided, and the expression stability and efficiency of exogenous genes in iPSC are improved.
Smart Images

Figure CN118910164A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, in particular to a plasmid vector and a construction method, and an exogenous gene expression system and a method thereof for constructing an IFN-γ-induced exogenous gene expression system in iPSC using the plasmid vector. Background Art
[0002] Cell and Gene Therapy (CGT) is a new generation of therapy that uses allogeneic or autologous isolated and cultured cells or genetically engineered vectors as drugs to treat diseases after completing cell or gene vector transformation and large-scale production in vitro. However, CGT in a broad sense is not a single cell or gene vector therapy, but rather the transformation of target cells through precise genetic modification so that they carry new functions of genetic modification and are used for disease treatment. This genetically engineered cell therapy, as a "living cell drug" with modified genetic background, may become a hot development direction in the field of CGT drug research and development in the future. The launch of CAR-T immune cell drugs is a representative example, marking the success of cell therapy methods that are genetically modified through genetic engineering technology.
[0003] Induced pluripotent stem cells (iPSCs) are a type of cell similar to embryonic stem cells obtained by reprogramming somatic cells. They have unlimited proliferation capacity and the potential to differentiate into various adult cell types. Therefore, iPSCs can be used as a cell source for various functional cells and can be cultured on a large scale and developed into various cell drugs without ethical restrictions.
[0004] In recent years, with the increasing maturity of iPSC technology, technical strategies based on gene modification of iPSC to achieve new functions of cell therapy have been widely used in the development of cell drugs. However, in iPSC, various mammalian expression systems are difficult to work effectively or express unevenly, which greatly limits the expression of exogenous genes in iPSC. Conventional mammalian gene engineering expression systems are most typically plasmid expression systems with constitutive promoters and recombinant lentiviral vector expression systems. These expression systems have a variety of exogenous gene expression regulatory elements, especially various exogenous promoters and transcription termination sequences. In the iPSC genome and epigenetic background, these exogenous regulatory elements are easily affected by epigenetic modification and reduce their functions. Therefore, it is necessary to design a plasmid vector and a construction method and to use the plasmid vector to construct an exogenous gene expression system and method in response to IFN-γ induction in iPSC. Summary of the invention
[0005] In order to overcome the defects in the prior art, a plasmid vector and a construction method are provided, and an exogenous gene expression system and a method thereof for constructing an IFN-γ-induced exogenous gene expression system in iPSC using the plasmid vector are provided.
[0006] The present invention is achieved through the following scheme:
[0007] A plasmid vector comprises a gene cutting vector and a template repair vector.
[0008] The gene cutting vector is an sgRNA and Cas9 protein expression vector targeting the B2M gene termination codon; the template repair vector has 600bp DNA sequences on both sides of the cutting site near the B2M gene termination codon as wings, into which a plasmid vector with HLA-G, CD47 and EGFP gene coding sequences is inserted.
[0009] The gene cutting vector uses the px459 vector as the skeleton to construct a gRNA / Cas9 expression vector. The gene expression structure of the gRNA / Cas9 expression vector is: U6 promoter sequence + B2M-TAG-sgRNA transcription sequence + EF1a promoter + Cas9 coding sequence, that is, the gene cutting vector, and the gene cutting vector is named px459-B2M-TAG-sgRNA;
[0010] The template repair vector uses the pUC57 cloning vector as a backbone, and comprises a homologous sequence (LA) upstream of the cleavage site, a protein fusion linker sequence, an HLA-G coding sequence, a P2A sequence, a CD47 gene coding sequence, a T2A sequence, an EGFP coding sequence, and a homologous sequence (RA) downstream of the cleavage site, namely, a template repair vector, and its nucleic acid sequence is shown in SEQ ID NO2. The template repair vector is named pUC57-HLA-G-CD47-EGFP.
[0011] A method for constructing a plasmid vector, the method comprising the following steps:
[0012] Construction of gene cutting vector: The DNA sequence near the stop codon site of the B2M gene was selected as the candidate target sequence, and the sgRNA was designed and optimized using the online CRISPOR program, named B2M-TAG-sgRNA, whose nucleic acid sequence is shown in SEQ ID NO1;
[0013] The complementary single-stranded DNA sequence of B2M-TAG-sgRNA was synthesized by primers and mixed in equal proportions in a 20 μl reaction system, denatured at 95°C for 5 minutes, and annealed at room temperature for 2 hours to synthesize double-stranded DNA;
[0014] The double-stranded DNA sequence was ligated with the pSpCas9(BB)-2A-Puro(PX459) vector linearized by BbSI, positive clones were picked and sequenced for verification, and the gene cutting vector was constructed, which was named px459-B2M-TAG-sgRNA;
[0015] Construction of gene template repair vector: The HLA-G, CD47 and EGFP gene coding sequences were connected through P2A and T2A sequences and designed to be placed in the open reading frame of the B2M gene; the gene template repair vector sequence was designed as: B2M gene cleavage site upstream homology arm sequence LA (without stop codon) + linker sequence + HLA-G coding sequence + P2A sequence + CD47 coding sequence + T2A sequence + EGFP sequence (including stop codon) + B2M gene cleavage site downstream homology arm sequence RA, the above sequences were cloned into the pUC57-mini vector after whole gene synthesis, and the constructed vector was named pUC57-HLA-G-CD47-EGFP.
[0016] An exogenous gene expression system in response to IFN-γ induction in iPSCs constructed using a plasmid vector, wherein the exogenous gene expression system refers to an iPS cell line that can regulate and highly express exogenous genes under IFN-γ stimulation constructed using CRISPR / Cas9 technology;
[0017] The gene cutting vector px459-B2M-TAG-sgRNA and the template repair vector pUC57-HLA-G-CD47-EGFP were co-electroporated into iPS cells, so that the HLA-G-CD47-EGFP gene fragment was integrated downstream of the B2M gene, the HLA-G and B2M genes were fused and expressed, and CD47 and EGFP were expressed independently.
[0018] A method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs using a plasmid vector, the method comprising the following steps:
[0019] IFN-γ-induced electroporation and screening of iPS cells expressing exogenous genes: Using the 4D nucleofector X electroporation system and P3 Primary cell kit, iPS cells and plasmids were mixed with 20 μl electroporation buffer, and screening was performed 48 hours after electroporation. An empty vector electroporation group was set up for resistance screening at the same time. When all cells in the empty vector electroporation group were apoptotic, the iPS cells in the electroporation experimental group were replaced with normal complete culture medium and continued to be cultured. When the cell proliferation was stable and in good condition, the IFN-γ-induced expression iPS cell line was obtained;
[0020] Construction of iPS cell line expressing exogenous genes induced by IFN-γ: The IFN-γ-induced iPS cell line was obtained by digestion and dispersion with Accutase, and a single cell suspension was prepared. After cell counting, 800 to 1000 iPS cells were inoculated in a 6 cm dish coated with Laminin-521 for continuous culture, and the medium was changed every day. After 7 days of culture, monoclonal iPS cells were observed under a microscope and picked and inoculated in a 48-well plate coated with Laminin-521 for further amplification and culture. Monoclonal cell lines were amplified and correctly identified by PCR genotype and flow cytometry phenotype, which was the iPS cell line expressing exogenous genes induced by IFN-γ.
[0021] In the construction of IFN-γ-induced expression iPS cell line, iPS cells were electroporated using 10 6 iPS cells and 3 μg or 4 μg plasmid were mixed with 20 μl of electroporation buffer.
[0022] The molar ratio of the gene cutting vector px459-B2M-TAG-sgRNA to the template repair vector pUC57-HLA-G-CD47-EGFP in the plasmid is 1:3.
[0023] The IFN-γ induced iPS cell screening for exogenous gene expression used 0.2 μg / ml puromycin.
[0024] The specific steps of electroporation are: adding to a well of an electroporation strip, electroporating using a DS130 or CM198 program, adding 900 μl of complete culture medium to the electroporated iPS cells, incubating in a 5% carbon dioxide incubator at 37°C for 30 minutes, and transferring to a 12-well plate to continue culturing for 48 hours.
[0025] The beneficial effects of the present invention are:
[0026] The present invention provides an exogenous gene expression system in response to IFN-γ induction in iPSCs. The expression system controls the expression levels of multiple introduced exogenous genes by IFN-γ without introducing regulatory sequences such as exogenous promoters and transcription termination sequences, with the help of endogenous expression regulatory elements of iPS cell B2M genes. That is, when there is no IFN-γ treatment, the exogenous genes are expressed at a low physiological level together with the B2M gene, and when there is IFN-γ treatment, the exogenous genes are expressed at a high level, thereby effectively avoiding the intervention of exogenous gene expression regulatory elements and the heterogeneity of their regulation of exogenous gene expression. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 :Plasmid vector structure used to construct IFN-γ-iPSC inducible expression system;
[0028] Figure 2:Schematic diagram of the principle of IFN-γ-iPSC inducible expression system;
[0029] Figure 3 :Flow cytometric detection of gene knock-in efficiency after iPSC electroporation with different doses of cutting vector and template repair vector;
[0030] Figure 4 :Flow cytometric identification of monoclonal cell lines of IFN-γ-iPSC inducible expression system;
[0031] Figure 5 :IFN-γ-iPSC inducible expression system 18 # and 53 # The clones were photographed fluorescently after IFN-γ treatment;
[0032] Figure 6 :IFN-γ-iPSC inducible expression system monoclonal cell line 18 # and 53 # The expression levels of HLA-G, CD47 and GFP proteins were detected by flow cytometry under IFN-γ treatment and non-treatment conditions.
[0033] Figure 7 :qPCR validation of IFN-γ-iPSC inducible expression system 18 # and 53 # The expression levels of HLA-G, CD47 and GFP proteins in clones were changed under IFN-γ treatment and non-treatment conditions. DETAILED DESCRIPTION
[0034] The preferred embodiments of the present invention are further described below:
[0035] A plasmid vector comprises a gene cutting vector and a template repair vector.
[0036] The gene cutting vector is an sgRNA and Cas9 protein expression vector targeting the B2M gene termination codon; the template repair vector has 600bp DNA sequences on both sides of the cutting site near the B2M gene termination codon as wings, into which a plasmid vector with HLA-G, CD47 and EGFP gene coding sequences is inserted.
[0037] The gene cutting vector uses the px459 vector as the skeleton to construct a gRNA / Cas9 expression vector. The gene expression structure of the gRNA / Cas9 expression vector is: U6 promoter sequence + B2M-TAG-sgRNA transcription sequence + EF1a promoter + Cas9 coding sequence, that is, the gene cutting vector, and the gene cutting vector is named px459-B2M-TAG-sgRNA;
[0038] The template repair vector uses the pUC57 cloning vector as a backbone, and comprises a homologous sequence (LA) upstream of the cleavage site, a protein fusion linker sequence, an HLA-G coding sequence, a P2A sequence, a CD47 gene coding sequence, a T2A sequence, an EGFP coding sequence, and a homologous sequence (RA) downstream of the cleavage site, namely, a template repair vector, and its nucleic acid sequence is shown in SEQ ID NO2. The template repair vector is named pUC57-HLA-G-CD47-EGFP.
[0039] SEQ ID NO2:
[0040]
[0041] A method for constructing a plasmid vector, the method comprising the following steps:
[0042] Construction of gene cutting vector: The DNA sequence near the stop codon site of the B2M gene was selected as the candidate target sequence, and the sgRNA was designed and optimized using the online CRISPOR program, named B2M-TAG-sgRNA, whose nucleic acid sequence is shown in SEQ ID NO1;
[0043] SEQ ID NO1: gacatgtaagcagcatg.
[0044] The complementary single-stranded DNA sequence of B2M-TAG-sgRNA was synthesized by primers and mixed in equal proportions in a 20 μl reaction system, denatured at 95°C for 5 minutes, and annealed at room temperature for 2 hours to synthesize double-stranded DNA;
[0045] The double-stranded DNA sequence was ligated with the pSpCas9(BB)-2A-Puro(PX459) vector linearized by BbSI, positive clones were picked and sequenced for verification, and the gene cutting vector was constructed, which was named px459-B2M-TAG-sgRNA;
[0046] Construction of gene template repair vector: The HLA-G, CD47 and EGFP gene coding sequences were connected through P2A and T2A sequences and designed to be placed in the open reading frame of the B2M gene; the gene template repair vector sequence was designed as: B2M gene cleavage site upstream homology arm sequence LA (without stop codon) + linker sequence + HLA-G coding sequence + P2A sequence + CD47 coding sequence + T2A sequence + EGFP sequence (including stop codon) + B2M gene cleavage site downstream homology arm sequence RA, the above sequences were cloned into the pUC57-mini vector after whole gene synthesis, and the constructed vector was named pUC57-HLA-G-CD47-EGFP.
[0047] An exogenous gene expression system in response to IFN-γ induction in iPSCs constructed using a plasmid vector, wherein the exogenous gene expression system refers to an iPS cell line that can regulate and highly express exogenous genes under IFN-γ stimulation constructed using CRISPR / Cas9 technology;
[0048] The gene cutting vector px459-B2M-TAG-sgRNA and the template repair vector pUC57-HLA-G-CD47-EGFP were co-electroporated into iPS cells, so that the HLA-G-CD47-EGFP gene fragment was integrated downstream of the B2M gene, the HLA-G and B2M genes were fused and expressed, and CD47 and EGFP were expressed independently.
[0049] A method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs using a plasmid vector, the method comprising the following steps:
[0050] IFN-γ-induced electroporation and screening of iPS cells expressing exogenous genes: Using the 4D nucleofector X electroporation system and P3 Primary cell kit, iPS cells and plasmids were mixed with 20 μl electroporation buffer, and screening was performed 48 hours after electroporation. An empty vector electroporation group was set up for resistance screening at the same time. When all cells in the empty vector electroporation group were apoptotic, the iPS cells in the electroporation experimental group were replaced with normal complete culture medium and continued to be cultured. When the cell proliferation was stable and in good condition, the IFN-γ-induced expression iPS cell line was obtained;
[0051] Construction of iPS cell line expressing exogenous genes induced by IFN-γ: The IFN-γ-induced iPS cell line was obtained by digestion and dispersion with Accutase, and a single cell suspension was prepared. After cell counting, 800 to 1000 iPS cells were inoculated in a 6 cm dish coated with Laminin-521 for continuous culture, and the medium was changed every day. After 7 days of culture, monoclonal iPS cells were observed under a microscope and picked and inoculated in a 48-well plate coated with Laminin-521 for further amplification and culture. Monoclonal cell lines were amplified and correctly identified by PCR genotype and flow cytometry phenotype, which was the iPS cell line expressing exogenous genes induced by IFN-γ.
[0052] In the construction of IFN-γ-induced expression iPS cell line, iPS cells were electroporated using 10 6 iPS cells and 3 μg or 4 μg plasmid were mixed with 20 μl of electroporation buffer.
[0053] The molar ratio of the gene cutting vector px459-B2M-TAG-sgRNA to the template repair vector pUC57-HLA-G-CD47-EGFP in the plasmid is 1:3.
[0054] The IFN-γ induced iPS cell screening for exogenous gene expression used 0.2 μg / ml puromycin.
[0055] The specific steps of electroporation are: adding to a well of an electroporation strip, electroporating using a DS130 or CM198 program, adding 900 μl of complete culture medium to the electroporated iPS cells, incubating in a 5% carbon dioxide incubator at 37°C for 30 minutes, and transferring to a 12-well plate to continue culturing for 48 hours.
[0056] The application scenarios of the iPSC-IFN-γ inducible expression system of this application are:
[0057] (1) Overexpression and production of medicinal exosomes from iPSCs. During the large-scale expansion and culture process, iPSCs carrying exogenous gene knock-in do not require exogenous gene expression and the production of exosomes containing medicinal proteins, so IFN-γ treatment is not required. When iPSCs are expanded to a certain number and medicinal exosomes need to be produced, IFN-γ is added to express medicinal proteins and produce exosomes in large quantities.
[0058] (2) iPSC-derived cell or MSC drug development: iPSC-derived functional cells carrying exogenous genes or MSC carrying this expression system can be combined with IFN-γ therapy when transplanted into the human body for treatment. This can be used to regulate the secretion of exosomes or other proteins containing medicinal proteins by cellular drugs in vivo, thereby enhancing the effect of cell therapy.
[0059] In the present application, "iPSC" and "iPS cell" have the same meaning.
[0060] The present application is further described below in conjunction with specific embodiments:
[0061] Example 1: Construction of gene modification vector
[0062] Construction of B2M gene cutting vector: The DNA sequence near the stop codon site of the B2M gene was selected as the candidate target sequence, and the online CRISPOR program (http: / / crispor.tefor.net / ) was input to design and optimize the sgRNA, named B2M-TAG-sgRNA, whose nucleic acid sequence is
[0063] GACATGTAAGCAGCATCATGG (SEQ ID NO1).
[0064] The B2M-TAG-sgRNA complementary single-stranded DNA sequence was synthesized by primers and mixed in equal proportions in a 20 μl reaction system, denatured at 95°C for 5 minutes, and annealed at room temperature for 2 hours to synthesize double-stranded DNA. The B2M-TAG-sgRNA double-stranded DNA sequence was ligated with the BbSI-linearized pSpCas9(BB)-2A-Puro(PX459) (Addgene, 62988) vector, and positive clones were picked and sequenced to construct the px459-B2M-TAG-sgRNA vector ( Figure 1).
[0065] Construction of gene template repair vector: To verify that the iPSC-IFN-γ expression system can simultaneously regulate the expression of multiple genes, we connected the HLA-G, CD47 and EGFP gene coding sequences through P2A and T2A sequences, and designed them to be placed in the open reading frame of the B2M gene. The repair template vector sequence is designed as follows: B2M gene cleavage site upstream homology arm sequence LA (without stop codon) + linker sequence + HLA-G coding sequence + P2A sequence + CD47 coding sequence + T2A sequence + EGFP sequence (including stop codon) + B2M gene cleavage site downstream homology arm sequence RA. The above sequences were cloned into the pUC57-mini vector (GenScript Biotech) after full gene synthesis, and the constructed vector was named pUC57-HLA-G-CD47-EGFP (see for details). Figure 1 ).
[0066] Example 2: Design and construction of IFN-γ-inducible expression iPS cell line
[0067] According to our design of iPSC-IFN-γ inducible expression system,
[0068] px459-B2M-TAG-sgRNA and pUC57-HLA-G-CD47-EGFP were co-transfected into iPS cells to integrate the HLA-G-CD47-EGFP gene fragment downstream of the B2M gene, so that the HLA-G and B2M genes were fused and expressed, and CD47 and EGFP were expressed independently (see for details). Figure 2 ). The specific construction process is as follows:
[0069] iPSC electroporation and resistance screening: 10 6iPS cells and 3 μg or 4 μg plasmid (the molar ratio of px459-B2M-TAG-sgRNA to pUC57-HLA-G-CD47-EGFP was 1:3) were mixed with 20 μl of electroporation buffer and added to one well of the electroporation strip. The electroporation was performed using the DS130 program. The electroporated iPS cells were added with 900 μl of complete culture medium and incubated in a 37°C, 5% carbon dioxide incubator for 30 minutes. The cells were transferred to a 12-well plate for culture. After 48 hours of electroporation, 0.2 μg / ml The empty vector electroporation group was screened with puromycin, and the empty vector electroporation group was set up for resistance screening at the same time. When all the cells in the empty vector electroporation group were apoptotic, the iPS cells in the electroporation experimental group were replaced with normal complete culture medium and continued to be cultured. When the cell proliferation was stable and in good condition, the IFN-γ-induced expression iPS cell line was obtained. The two transduction groups and the non-transfected group were detected by flow cytometry. The results showed that GFP-positive cell groups appeared on the right side of the 3μg and 4μg plasmid electroporation groups, and B2M staining flow cytometry showed that some low-expressing B2M cell groups appeared (see Figure 3 ), among which the GFP-positive and B2M low-expressing cell population was proposed to be IFN-γ-induced expression iPS cells.
[0070] Picking of IFN-γ-induced iPS cell lines: Use Accutase (StemCell) to digest and disperse IFN-γ-induced iPS cell lines to prepare single cell suspensions. After counting the cells, take 800 to 1000 iPSCs and inoculate them in 6 cm dishes coated with Laminin-521 (StemCell) for continuous culture. Change the medium every day. After 7 days of culture, observe the single clones under an inverted microscope and pick them and inoculate them in 48-well plates coated with Laminin-521 for further expansion and culture. Collect each clone cell and use flow cytometry to detect GFP expression. The results show that among the 7 cell lines tested, 4 are monoclonal and express GFP, and the other 3 cell lines are polyclonal cells (see Figure 4 We selected monoclonal cell lines 18 # and 53 # Perform functional verification.
[0071] Example 3: Functional verification of IFN-γ-induced expression iPS cell line
[0072] The candidate IFN-γ-induced expression iPS cell line 18 obtained in Example 2 # , 53 # and iPS cell lines at 3×10 4 / cm 2The cells were inoculated into 24-well plates and duplicate wells were set up. The medium was changed every day. Two days after inoculation, one well was replaced with a medium containing 25 ng / ml IFN-γ, and the other well was replaced with a medium without IFN-γ. After two days of treatment with the above medium change method, GFP-expressing cells were observed under an inverted fluorescence microscope. The results showed that 18 cells treated with IFN-γ showed a decrease in GFP expression. # , 53 # The cell lines expressed GFP, while the IFN-γ untreated group did not express GFP (see Figure 5 ), the cells of each group were digested with Accutase and collected, and each group of cells was divided into three parts, and stained with B2M-PE, HLA-G-PE and CD47-APC antibodies respectively. The results of flow cytometry showed that compared with the IFN-γ untreated group, the B2M protein of the three cell lines treated with IFN-γ was expressed at a high level, among which the gene-modified iPS cell line 18 # and 53 # Under IFN-γ stimulation, HLA-G, CD47 and GFP are expressed at high levels (see Figure 6 ). In order to fully verify the gene-modified iPS cell line 18 # and 53 # We used the same dose of IFN-γ to treat 18 # and 53 # The expression of HLA-G and CD47 genes was detected by qPCR. The results showed that compared with IFN-γ untreated cells, gene-modified iPSC-18 # Under IFN-γ stimulation, the expression of HLA-G and CD47 in iPSC-53 clones increased by about 20 times. # The expression of HLA-G and CD47 in the clones increased by about 40 times ( Figure 7 ).
[0073] Although the technical solutions of the present invention have been described and listed in detail, it should be understood that it is obvious to those skilled in the art to make modifications to the above embodiments or adopt equivalent alternatives. These modifications or improvements made without departing from the spirit of the present invention are within the scope of protection required by the present invention.
Claims
1. A plasmid vector, characterized in that: The plasmid vector comprises a gene cutting vector and a template repair vector.
2. The plasmid vector according to claim 1, characterized in that: The gene cutting vector is an sgRNA and Cas9 protein expression vector targeting the B2M gene termination codon; the template repair vector has 600bp DNA sequences on both sides of the cutting site near the B2M gene termination codon as wings, into which a plasmid vector with HLA-G, CD47 and EGFP gene coding sequences is inserted.
3. The plasmid vector according to claim 2, characterized in that: The gene cutting vector uses the px459 vector as the skeleton to construct a gRNA / Cas9 expression vector. The gene expression structure of the gRNA / Cas9 expression vector is: U6 promoter sequence + B2M-TAG-sgRNA transcription sequence + EF1a promoter + Cas9 coding sequence, that is, the gene cutting vector, and the gene cutting vector is named px459-B2M-TAG-sgRNA; The template repair vector uses the pUC57 cloning vector as a backbone, and comprises a homologous sequence (LA) upstream of the cleavage site, a protein fusion linker sequence, an HLA-G coding sequence, a P2A sequence, a CD47 gene coding sequence, a T2A sequence, an EGFP coding sequence, and a homologous sequence (RA) downstream of the cleavage site, namely, a template repair vector, and its nucleic acid sequence is shown in SEQ ID NO2. The template repair vector is named pUC57-HLA-G-CD47-EGFP.
4. A method for constructing a plasmid vector as claimed in any one of claims 1 to 3, characterized in that: The method comprises the following steps: Construction of gene cutting vector: The DNA sequence near the stop codon site of the B2M gene was selected as the candidate target sequence, and the sgRNA was designed and optimized using the online CRISPOR program, named B2M-TAG-sgRNA, whose nucleic acid sequence is shown in SEQ ID NO1; The complementary single-stranded DNA sequence of B2M-TAG-sgRNA was synthesized by primers and mixed in equal proportions in a 20 μl reaction system, denatured at 95°C for 5 minutes, and annealed at room temperature for 2 hours to synthesize double-stranded DNA; The double-stranded DNA sequence was ligated with the pSpCas9(BB)-2A-Puro(PX459) vector linearized by BbSI, positive clones were picked and sequenced for verification, and the gene cutting vector was constructed, which was named px459-B2M-TAG-sgRNA; Construction of gene template repair vector: The HLA-G, CD47 and EGFP gene coding sequences were connected through P2A and T2A sequences and designed to be placed in the open reading frame of the B2M gene; the gene template repair vector sequence was designed as: B2M gene cleavage site upstream homology arm sequence LA (without stop codon) + linker sequence + HLA-G coding sequence + P2A sequence + CD47 coding sequence + T2A sequence + EGFP sequence (including stop codon) + B2M gene cleavage site downstream homology arm sequence RA, the above sequences were cloned into the pUC57-mini vector after whole gene synthesis, and the constructed vector was named pUC57-HLA-G-CD47-EGFP.
5. An exogenous gene expression system in response to IFN-γ induction in iPSCs constructed using the plasmid vector according to any one of claims 1 to 3, characterized in that: The exogenous gene expression system refers to an iPS cell line that can regulate and highly express exogenous genes under IFN-γ stimulation, constructed by CRISPR / Cas9 technology; The gene cutting vector px459-B2M-TAG-sgRNA and the template repair vector pUC57-HLA-G-CD47-EGFP were co-electroporated into iPS cells, so that the HLA-G-CD47-EGFP gene fragment was integrated downstream of the B2M gene, the HLA-G and B2M genes were fused and expressed, and CD47 and EGFP were expressed independently.
6. A method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs using the plasmid vector according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: IFN-γ-induced electroporation and screening of iPS cells expressing exogenous genes: Using the 4D nucleofector X electroporation system and P3Primary cell kit, iPS cells and plasmids were mixed with 20 μl electroporation buffer, and screening was performed 48 hours after electroporation. An empty vector electroporation group was set up for resistance screening at the same time. When all cells in the empty vector electroporation group were apoptotic, the iPS cells in the electroporation experimental group were replaced with normal complete culture medium and continued to be cultured. When the cell proliferation was stable and in good condition, the IFN-γ-induced expression iPS cell line was obtained; Construction of iPS cell line expressing exogenous genes induced by IFN-γ: The IFN-γ-induced iPS cell line was obtained by digestion and dispersion with Accutase, and a single cell suspension was prepared. After cell counting, 800 to 1000 iPS cells were inoculated in a 6 cm dish coated with Laminin-521 for continuous culture, and the medium was changed every day. After 7 days of culture, monoclonal iPS cells were observed under a microscope and picked and inoculated in a 48-well plate coated with Laminin-521 for further amplification and culture. Monoclonal cell lines were amplified and correctly identified by PCR genotype and flow cytometry phenotype, which was the iPS cell line expressing exogenous genes induced by IFN-γ.
7. The method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs according to claim 6, characterized in that: In the construction of IFN-γ-induced expression iPS cell line, iPS cells were electroporated and 10 6 iPS cells and 3 μg or 4 μg plasmid were mixed with 20 μl of electroporation buffer.
8. The method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs according to claim 7, characterized in that: The molar ratio of the gene cutting vector px459-B2M-TAG-sgRNA to the template repair vector pUC57-HLA-G-CD47-EGFP in the plasmid is 1:
3.
9. The method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs according to claim 6, characterized in that: The IFN-γ induced iPS cell screening for exogenous gene expression used 0.2 μg / ml puromycin.
10. The method for constructing an exogenous gene expression system in response to IFN-γ induction in iPSCs according to claim 6, characterized in that: The specific steps of electroporation are: adding to a well of an electroporation strip, electroporating using a DS130 or CM198 program, adding 900 μl of complete culture medium to the electroporated iPS cells, incubating in a 5% carbon dioxide incubator at 37°C for 30 minutes, and transferring to a 12-well plate to continue culturing for 48 hours.
Citation Information
Patent Citations
GS-DHFRmut double-gene screening expression vector, and preparation method and application thereof
CN103468742A
Application of super enhancer gene sequence in promoting expression of human B2M gene
CN113801881A
Low-immunogenicity iPSC cell strain
CN116515740A
